Drugs / YB-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05986981 | Aug → Dec 2023 | cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YB-01 | “The therapeutic cancer vaccine YB-01 is a therapeutic cancer vaccine formulation developed by the Department of Nuclear Medicine of Peking Union Medical College Hospital and...” NCT05986981 ↗ |
| Target | MUC1 | “YB-01 vaccine targets MUC1 and enhances humoral and cell-mediated immune responses through immunity to MUC1 peptide or MUC1 peptide-activated dendritic cells (DC).” NCT05986981 ↗ |